Skip to main content

Table 1 Giant cell arteritis disease characteristics at the time of diagnosis

From: Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study

n (%)

All patients, N = 24

History of ESR ≥ 50 mm/h

17 (70.8)

History of CRP ≥ 24.5 mg/L

21 (87.5)

Localized headache

16 (66.7)

Scalp tenderness

6 (25.0)

Temporal artery tenderness

7 (29.2)

Temporal artery decreased pulsation

2 (8.3)

Ischemia-related vision loss

2 (8.3)

Otherwise unexplained mouth or jaw pain upon mastication

8 (33.3)

PMR symptoms

15 (62.5)

Temporal artery biopsy performed

15 (62.5)

Positive temporal artery biopsy results

13 (54.2)

Angiography or cross-sectional imaging performed

20 (83.3)

 Magnetic resonance angiography

13 (65.0)

 Positron emission tomography-computed tomography

6 (30.0)

 Ultrasound

1 (5.0)

Large vessel vasculitis

18 (75.0)

  1. CRP C-reactive protein, ESR Erythrocyte sedimentation rate, PMR Polymyalgia rheumatica